-
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
•
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating its GLP-1 receptor agonist, tirzepatide, in adults with obesity or overweight accompanied by comorbidities, excluding type 2 diabetes (T2D). The study successfully met its two co-primary endpoints, demonstrating superiority over placebo in weight loss after…
-
Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial
•
China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional clinical trial approval from the National Medical Products Administration (NMPA) for its investigational bispecific antibody (BsAb), SIM0237. This molecule, targeting both PD-L1 and IL-15, is set to be evaluated as a novel treatment for non-muscular…
-
Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023
•
Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results of Phase I clinical studies for two of its pipeline candidates at the 2023 European Society for Medical Oncology (ESMO) Congress. The spotlight will be on ABSK011, a small-molecule FGFR4 inhibitor, and ABSK043, an in-house…
-
MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced the successful completion of the first two clinical applications of its third-generation transcatheter aortic valve implantation (TAVI) product. This advanced medical device features a recyclable and controllable bend delivery system, which was…
-
Suzhou Inhal Pharma Secures Series A Funding for Expansion and Clinical Advances
•
Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of inhalation formulations, inhalers, and filling equipment, has reportedly secured over RMB 50 million (USD 6.8 million) in a Series A financing round. The investment round was spearheaded by Shining Capital, marking a significant boost for…
-
CANbridge’s Maralixibat Receives Priority Review for PFIC Treatment in China
•
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced that a New Drug Application (NDA) for its maralixibat (CAN108) has been accepted for review by the National Medical Products Administration (NMPA) in China, with the added benefit of priority review status. This marks a significant step forward in…
-
WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the launch of its innovative biotechnology patent platform, WuXiUI. Developed based on the ultra-enhanced flow plus cell culture process, this platform is designed to be suitable for mainstream cell lines and various molecular types, marking a…
-
Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has announced the commencement of a Phase III clinical study for its drug ET-26 (methoxyethyl etomidate). This marks a significant milestone in the development of new anesthetic solutions, with ET-26 being evaluated as an induction therapy…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
